Welcome to our dedicated page for SBC Medical Group Holdings Incorporated news (Ticker: SBC), a resource for investors and traders seeking the latest updates and insights on SBC Medical Group Holdings Incorporated stock.
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) is frequently featured in financial and industry news as a global provider of consulting and management services to medical corporations and their clinics. News coverage of SBC often focuses on its expansion in aesthetic medicine, its multi-brand clinic strategy, and its capital markets activity as a Nasdaq-listed company included in the Russell 3000 Index.
Readers following SBC Medical news can expect updates on international expansion initiatives, such as partnerships and consulting agreements in markets like Thailand and Singapore, and strategic moves in the United States. Recent announcements include a strategic minority equity investment and collaboration framework with OrangeTwist, a U.S.-based MedSpa chain, marking SBC’s formal entry into the U.S. medical aesthetics market. News also covers partnerships with regional operators like BLEZ ASIA in Thailand, where SBC provides management support and clinical protocol guidance for new dermatology-focused clinics.
Another major category of SBC news involves corporate and capital strategy. The company issues press releases on quarterly financial results, including revenue trends, operating income, EBITDA, and key operating metrics such as the number of franchise locations and customer visits. SBC also reports on its capital strategy, including the effectiveness of a shelf registration statement on Form S-3 and authorization of a share repurchase program, as well as its inclusion in major equity indexes.
In addition, SBC news highlights strategic investments and acquisitions, such as tender offers for shares of Waqoo, Inc., a regenerative medicine-focused research and development company. These transactions are presented as part of SBC’s broader plan to enhance its healthcare technology capabilities and support long-term growth in aesthetic and related medical fields. Investors and observers can use this news feed to monitor SBC’s clinic network growth, international partnerships, and financial performance over time.
SBC Medical (Nasdaq: SBC) reported Q4 2025 and full-year results on March 27, 2026. Q4 revenue was $40 million (-11% YoY) and Q4 EPS was $0.14 (+133% YoY). Full-year revenue was $174 million (-15% YoY) with net income $51 million (+9% YoY) and EPS $0.50 (+4% YoY).
EBITDA was $70 million for FY2025 (-21% YoY) and EBITDA margin was 40% (down 3 percentage points). Franchise locations reached 283 and annual customer visits were 6.63 million. Management emphasized structural changes and priorities for 2026 including multi-brand dermatology and international expansion.
SBC Medical (Nasdaq: SBC) launched SBC Wellness 2.0, a wellness and longevity platform combining aesthetic healthcare, preventative care, and data-driven health management.
The program targets the longevity market projected at about $800B in 2025 and $2T by 2035, and will leverage SBC Medical’s 283 clinics and ~6.5 million annual visits in Japan to build subscription-like corporate contracts and self-pay services.
SBC Medical (Nasdaq: SBC) will open the flagship NEO Skin Clinic Ginza on March 28, 2026, in a prime location near GINZA SIX. The clinic features VIP rooms for international clients, leverages a network of 283 affiliated clinics (as of Dec 2025), and builds on the Ebisu validation from April 2025.
The brand uses VISIA skin diagnostics, appoints Japanese and Korean technical advisors, offers internationally aligned pricing, and plans further expansion into Nagoya and Kobe by end-2026 to support multi-brand growth and higher-value services.
SBC Medical (Nasdaq: SBC) will report fourth-quarter and full-year 2025 financial results before U.S. market open on March 27, 2026.
Management will host an earnings conference call on March 27, 2026 at 8:30 a.m. ET with prepared remarks and a Q&A. The earnings release, slides, and archived webcast will be posted on the company investor relations website.
SBC Medical (Nasdaq: SBC) appointed Sheng-FU Hsiao as Chief Technology Officer effective March 1, 2026, to lead an AI-driven digital transformation across 283 global locations and leverage data from 6.63 million annual patient visits to build a scalable Automated Management Infrastructure.
Key initiatives include AI call centers, core system modernization to microservices, expanded back-office automation, an "AI Concierge," "AI Mirrors," and global rollout of an AI-native medical OS to improve productivity, transparency, and reproducibility.
SBC Medical (Nasdaq: SBC) announced a strategic alliance between Medical Corporation Nasukai (operator of Shonan Beauty Clinic) and Daibi Medical Aesthetics in Shanghai to share clinical expertise, operations and safety practices.
The partnership aims to boost Shonan Beauty Clinic brand recognition in China, support inbound medical tourism to Japan and explore cross-border revenue opportunities; inbound visits rose from ~600 in early 2024 to ~1,700 by end-2025.
SBC Medical Group Holdings (Nasdaq:SBC) received a Buy-Extended rating with a $9.00 12-month price target, implying material upside from the $4.44 close on January 6, 2026. The note highlights SBC's strategic minority investment and structured collaboration with U.S. MedSpa chain OrangeTwist (24 locations across 6 states) as the company's formal entry into the U.S. medical aesthetics market.
Key financials cited include sequential revenue stabilization in Q3:25, a strong balance sheet with net cash ~40% of market capitalization, and low leverage (Debt/MV Equity 5%), supporting SBC's phased international expansion and a target to grow from 258 to 1,000 clinics over ten years.
OrangeTwist announced a strategic alliance and minority investment with SBC Medical Group Holdings (Nasdaq: SBC) on January 7, 2026, as part of an accelerated national growth strategy. The companies will collaborate on clinical protocol development, advanced technology integration, and operational scalability to support domestic and international expansion.
Concurrently, OrangeTwist acquired six med spa locations in Colorado and Nevada, growing its footprint to 24 locations across six states: California, Texas, Washington, Nevada, Colorado, and New Jersey. The company is backed by private equity firms Hildred and Athyrium Capital Management to support continued organic expansion and strategic acquisitions.
SBC Medical (Nasdaq: SBC) completed a minority equity investment and structured collaboration with U.S. MedSpa chain OrangeTwist on January 5, 2026, marking SBC Medical's formal entry into the U.S. market.
Key facts: OrangeTwist operates 24 locations across six U.S. states; SBC Medical supports 258 affiliated clinics and manages more than six million patient visits annually. The deal begins a multi‑year, three‑phase global expansion roadmap (Phase 1: Entry 2025–2026) focused on cross‑border synergies in clinical protocols, technology, and operations.
SBC (NASDAQ: SBC) announced an updated capital strategy including an effective Form S-3 registration statement and a $20.0 million share repurchase program.
The SEC declared the Form S-3 effective on December 30, 2025, enabling the company to offer up to $50 million of common or preferred stock from time to time; no securities are being sold under the shelf at this time. The Form S-3 also covers securities related to the company's business combination that closed on September 17, 2024.
The board authorized a $20.0 million repurchase program that may run through December 31, 2026, use open-market and private transactions, and may utilize Rule 10b5-1 plans; repurchases are discretionary and may be limited by debt agreements and market conditions.